vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与CarParts.com, Inc.（PRTS）财务数据对比。点击上方公司名可切换其他公司
CATALYST PHARMACEUTICALS, INC.的季度营收约是CarParts.com, Inc.的1.3倍（$152.6M vs $120.4M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs -9.6%，领先44.1%），CATALYST PHARMACEUTICALS, INC.同比增速更快（7.6% vs -9.8%），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs -8.6%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
GPC是一家总部位于美国佐治亚州亚特兰大的汽车与工业零部件分销商，1928年由弗雷泽兄弟创立，目前拥有约六万名员工。除美国本土市场外，公司业务还覆盖澳大拉西亚、比利时、加拿大、法国、德国、墨西哥、荷兰、波兰及英国，旗下拥有知名汽车零部件零售商NAPA Auto Parts和工业零部件分销商Motion。
CPRX vs PRTS — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $120.4M |
| 净利润 | $52.7M | $-11.6M |
| 毛利率 | 82.9% | 33.2% |
| 营业利润率 | 40.5% | — |
| 净利率 | 34.5% | -9.6% |
| 营收同比 | 7.6% | -9.8% |
| 净利润同比 | -5.8% | 25.0% |
| 每股收益（稀释后） | $0.40 | $-0.82 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | $120.4M | ||
| Q3 25 | $148.4M | $127.8M | ||
| Q2 25 | $146.6M | $151.9M | ||
| Q1 25 | $141.4M | $147.4M | ||
| Q4 24 | $141.8M | $133.5M | ||
| Q3 24 | $128.7M | $144.8M | ||
| Q2 24 | $122.7M | $144.3M | ||
| Q1 24 | $98.5M | — |
| Q4 25 | $52.7M | $-11.6M | ||
| Q3 25 | $52.8M | $-10.9M | ||
| Q2 25 | $52.1M | $-12.7M | ||
| Q1 25 | $56.7M | $-15.3M | ||
| Q4 24 | $55.9M | $-15.4M | ||
| Q3 24 | $43.9M | $-10.0M | ||
| Q2 24 | $40.8M | $-8.7M | ||
| Q1 24 | $23.3M | — |
| Q4 25 | 82.9% | 33.2% | ||
| Q3 25 | 84.7% | 33.1% | ||
| Q2 25 | 85.9% | 32.8% | ||
| Q1 25 | 87.3% | 32.1% | ||
| Q4 24 | 84.7% | 32.5% | ||
| Q3 24 | 85.0% | 35.2% | ||
| Q2 24 | 87.4% | 33.5% | ||
| Q1 24 | 87.3% | — |
| Q4 25 | 40.5% | — | ||
| Q3 25 | 44.7% | -7.9% | ||
| Q2 25 | 45.2% | -8.2% | ||
| Q1 25 | 44.8% | -10.3% | ||
| Q4 24 | 44.3% | -11.6% | ||
| Q3 24 | 39.6% | -6.9% | ||
| Q2 24 | 44.2% | -6.0% | ||
| Q1 24 | 27.5% | — |
| Q4 25 | 34.5% | -9.6% | ||
| Q3 25 | 35.6% | -8.5% | ||
| Q2 25 | 35.6% | -8.4% | ||
| Q1 25 | 40.1% | -10.4% | ||
| Q4 24 | 39.4% | -11.5% | ||
| Q3 24 | 34.1% | -6.9% | ||
| Q2 24 | 33.2% | -6.0% | ||
| Q1 24 | 23.6% | — |
| Q4 25 | $0.40 | $-0.82 | ||
| Q3 25 | $0.42 | $-0.19 | ||
| Q2 25 | $0.41 | $-0.23 | ||
| Q1 25 | $0.45 | $-0.27 | ||
| Q4 24 | $0.44 | $-0.28 | ||
| Q3 24 | $0.35 | $-0.17 | ||
| Q2 24 | $0.33 | $-0.15 | ||
| Q1 24 | $0.19 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $25.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $954.3M | $53.5M |
| 总资产 | $1.1B | $184.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | $25.8M | ||
| Q3 25 | $689.9M | — | ||
| Q2 25 | $652.8M | — | ||
| Q1 25 | $580.7M | — | ||
| Q4 24 | $517.6M | — | ||
| Q3 24 | $442.3M | — | ||
| Q2 24 | $375.7M | — | ||
| Q1 24 | $310.4M | — |
| Q4 25 | $954.3M | $53.5M | ||
| Q3 25 | $920.2M | $64.2M | ||
| Q2 25 | $856.0M | $62.4M | ||
| Q1 25 | $794.3M | $72.8M | ||
| Q4 24 | $727.6M | $85.2M | ||
| Q3 24 | $660.9M | $97.2M | ||
| Q2 24 | $608.7M | $103.9M | ||
| Q1 24 | $561.4M | — |
| Q4 25 | $1.1B | $184.9M | ||
| Q3 25 | $1.1B | $200.3M | ||
| Q2 25 | $971.9M | $189.6M | ||
| Q1 25 | $908.9M | $216.5M | ||
| Q4 24 | $851.4M | $210.6M | ||
| Q3 24 | $772.0M | $227.6M | ||
| Q2 24 | $706.4M | $238.0M | ||
| Q1 24 | $646.7M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | — |
| 自由现金流经营现金流 - 资本支出 | $44.9M | — |
| 自由现金流率自由现金流/营收 | 29.4% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | — | ||
| Q3 25 | $32.4M | $-6.4M | ||
| Q2 25 | $71.3M | $-25.6M | ||
| Q1 25 | $60.0M | $5.5M | ||
| Q4 24 | $70.9M | $1.8M | ||
| Q3 24 | $72.9M | $8.5M | ||
| Q2 24 | $64.1M | $-3.6M | ||
| Q1 24 | $31.9M | — |
| Q4 25 | $44.9M | — | ||
| Q3 25 | — | $-8.3M | ||
| Q2 25 | $71.3M | $-27.9M | ||
| Q1 25 | — | $3.4M | ||
| Q4 24 | $70.8M | $-631.0K | ||
| Q3 24 | $72.6M | $4.9M | ||
| Q2 24 | $64.1M | $-10.8M | ||
| Q1 24 | $31.7M | — |
| Q4 25 | 29.4% | — | ||
| Q3 25 | — | -6.5% | ||
| Q2 25 | 48.6% | -18.3% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | 49.9% | -0.5% | ||
| Q3 24 | 56.4% | 3.4% | ||
| Q2 24 | 52.3% | -7.5% | ||
| Q1 24 | 32.2% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 1.5% | ||
| Q2 25 | 0.0% | 1.5% | ||
| Q1 25 | 0.0% | 1.4% | ||
| Q4 24 | 0.1% | 1.8% | ||
| Q3 24 | 0.2% | 2.5% | ||
| Q2 24 | 0.0% | 4.9% | ||
| Q1 24 | 0.2% | — |
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 1.37× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.57× | — | ||
| Q1 24 | 1.37× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
PRTS
暂无分部数据
